These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 860733)

  • 1. Amikacin therapy of severe infections produced by gram-negative bacilli resistant to gentamicin.
    Valdivieso M; Bodey GP
    Am J Med Sci; 1977; 273(2):177-84. PubMed ID: 860733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Controlled comparison of amikacin and gentamicin.
    Smith CR; Baughman KL; Edwards CQ; Rogers JF; Lietman PS
    N Engl J Med; 1977 Feb; 296(7):349-53. PubMed ID: 319355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amikacin treatment of pulmonary infections involving gentamicin-resistant gram-negative bacilli.
    Bartlett JG
    Am J Med; 1977 Jun; 62(6):945-8. PubMed ID: 868911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Susceptibility of aerobic gram-negative bacilli to aminoglycosides. Effects of 45 months of amikacin as first-line aminoglycoside therapy.
    Saavedra S; Vera D; Ramírez-Ronda CH
    Am J Med; 1986 Jun; 80(6B):65-70. PubMed ID: 3014877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amikacin therapy for severe gram-negative sepsis. Emphasis on infections with gentamicin-resistant organisms.
    Tally FP; Louie TJ; Weinstein WM; Bartlett JG; Gorbach SL
    Ann Intern Med; 1975 Oct; 83(4):484-8. PubMed ID: 1101761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term amikacin use. Effects on aminoglycoside susceptibility patterns of gram-negative bacilli.
    Moody MM; de Jongh CA; Schimpff SC; Tillman GL
    JAMA; 1982 Sep; 248(10):1199-202. PubMed ID: 6809965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Control of emergence of multi-resistant gram-negative bacilli by exclusive use of amikacin.
    Ruiz-Palacios GM; Ponce de Leon S; Sifuentes J; Ponce de Leon S; Calva JJ; Huazano F; Ontiveros C; Ojeda F; Bobadilla M
    Am J Med; 1986 Jun; 80(6B):71-5. PubMed ID: 3089006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and microbiologic consequences of amikacin use during a 42-month period.
    Berk SL; Alvarez S; Ortega G; Verghese A; Holtsclaw-Berk SA
    Arch Intern Med; 1986 Mar; 146(3):538-41. PubMed ID: 3954526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amikacin therapy for serious gram-negative infection.
    Pollock AA; Berger SA; Richmond AS; Simberkoff MS; Rahal JJ
    JAMA; 1977 Feb; 237(6):562-4. PubMed ID: 576282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amikacin therapy for severe gram-negative sepsis: efficacy in infections involving gentamicin-resistant organisms.
    Tally FP; Louie TJ; O'Keefe P; Gorbach SL; Bartlett JG
    J Infect Dis; 1976 Nov; 134 SUPPL():S428-32. PubMed ID: 993634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibiotic resistance patterns during aminoglycoside restriction.
    Young EJ; Sewell CM; Koza MA; Clarridge JE
    Am J Med Sci; 1985 Dec; 290(6):223-7. PubMed ID: 3936358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Experimental study of the antibacterial activity and chemotherapeutic effectiveness of amikacin sulfate].
    Lobuseva AN; Kuznetsova SM; Samoĭlova LN
    Antibiot Med Biotekhnol; 1985 Oct; 30(10):776-80. PubMed ID: 4091515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and bacteriological evaluation of amikacin in severe gram-negative infections.
    Klastersky J; Van Beerse D; Schoutens E; De Temmerman P; Yourassowsky E
    J Clin Pharmacol; 1976 Apr; 16(4):213-22. PubMed ID: 770510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of amikacin sulfate (Amikin). A new aminoglycoside antibiotic.
    Schiffman DO
    JAMA; 1977 Oct; 238(14):1547-50. PubMed ID: 578232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gentamicin and amikacin---an in vitro comparison using 1000 clinical isolates.
    Forgan-Smith WR; McSweeney RJ
    Aust N Z J Med; 1978 Aug; 8(4):383-6. PubMed ID: 282852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amikacin therapy for serious gram-negative bacillary infections.
    Meyer RD; Lewis RP; Carmalt ED; Finegold SM
    Ann Intern Med; 1975 Dec; 83(6):790-800. PubMed ID: 1200524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antibacterial activity of amikacin towards gentamicin-resistant, Gram-negative bacilli].
    Nicoletti G; Russo G; Toscano MA; Gismondo MR
    Boll Ist Sieroter Milan; 1979 Jan; 57(6):713-7. PubMed ID: 121911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gentamicin-resistant gram-negative bacilli in hospital patients. Part II. In vitro aspects including susceptibility to tobramycin and amikacin.
    Block CS; Fabian B; Robinson RG
    S Afr Med J; 1978 Mar; 53(11):396-99. PubMed ID: 675374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gentamicin/amikacin-resistant gram-negative bacilli at Detroit General Hospital, 1975-1976.
    Jauregui L; Cushing RD; Lerner AM
    Am J Med; 1977 Jun; 62(6):882-8. PubMed ID: 868902
    [No Abstract]   [Full Text] [Related]  

  • 20. Amikacin: in vitro bacteriological studies, levels in human serum, lung and heart tissue, and clinical results.
    Faragó E; Kiss J; Gömöry A; Aranyosi J; Juhász I; Mihóczy L
    Int J Clin Pharmacol Biopharm; 1979 Nov; 17(11):421-8. PubMed ID: 511416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.